RLF-100 (aviptadil) quickly inhibits replication of new coronaviruses!

RLF-100 (aviptadil) is a synthetic human vascularactive intestinal polypeptide (VIP) that has been specified by the FDA for fast-track.
pharmaceutical companies NeuroRx and Relief announced today that RLF-100 (aviptadil) can significantly reduce the mortality rate from respiratory failure in critical COVID-19 patients.
, independent researchers report that RLF-100 (aviptadil) blocks the replication of the new coronavirus in human lung cells and mononucleoblasts.
vascularally active intestinal polypeptides (VIPs) were first discovered by Dr. Sami Said in 1970.
Although first found in the intestines, IT is now known that VIPs are produced throughout the body and are concentrated in the lungs.
more than 100 peer-reviewed studies have shown that VIP has effective anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury and inflammation.
most importantly, 70% of the body's VIPs bind to alve olivel type II cells, which are essential for the spread of oxygen to the body.
COVID-19-related deaths are mainly caused by respiratory failure.
the alveoli type II cells are known to have high levels of angiotensin conversion enzyme 2 (ACE2) receptor, ACE2 can be used as a way for SARS-CoV-2 to enter the cells.
these type II alveoli cells also have high concentrations of VIP receptors on their cell surfaces, so VIP is expected to specifically protect these cells from loss.
.